Canada's Immuno-Engineering and Biomanufacturing Hub

CIEBH brings together a coalition of more than 50 organizations representing the private, public, not-for-profit and academic sectors to bolster biomedical innovation. Our vision is to make Canada a global epicentre for developing next-generation immune-based therapeutics that can be rapidly produced domestically, using the latest breakthroughs in biomanufacturing, in response to future pandemics and other health threats. Our mission is to harness the collective research and training excellence of our partners to greatly increase Canadian capacity to translate scientific discoveries into patient-ready treatments at rapid speed — saving more lives, sooner.

CIEBH, led by UBC, is one of five national research hubs established through the integrated Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF) competition.